Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMAGE-1: IMM-101 + Gemcitabine in Advanced Pancreatic Cancer
NCT01303172Phase 2Completed
- Sponsor
- Immodulon Therapeutics
- Start
- Jun 2011
- Primary completion
- Jun 2014
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 5
01
Overview
A Phase 2 trial of IMM-101 in pancreatic ductal adenocarcinoma (PDAC), sponsored by Immodulon Therapeutics. Started Jun 2011; status: completed.
02
Drugs
IMM-101
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01303172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01303172.